PaperInsulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines
References (25)
- et al.
Treatment of pelvic sarcomas in adolescents and young adults with intensive combined modality therapy
Int J Radiat Oncol Biol Phys
(1987) - et al.
Treatment of sarcomas of the chest wall using intensive combined modality therapy
Int J Radiat Oncol Biol Phys
(1989) Ewing's sarcoma and related small round cell neoplasms in children
Am J Surg Pathol
(1986)- et al.
Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen
Cancer Res
(1988) - et al.
Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor
Oncogene
(1990) Peripheral and central primitive neuroectodermal tumors: A nosologic concept seeking a consensus
Arch Pathol Lab Med
(1986)- et al.
The monoclonal antibody HBA-71 modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor-I
Thymus
(1991) - et al.
Peripheral neuroectodermal sarcoma of soft tissue (peripheral neuroepithelioma): A pathological study of ten cases with differential diagnosis regarding other small, round-cell sarcomas
Human Pathol
(1989) - et al.
Malignant peripheral neuroectodermal tumors of childhood and adolescence
Virchows Arch
(1985) - et al.
Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study
J Clin Oncol
(1991)
Multidisciplinary treatment of primary Ewing's sarcoma of bone
Cancer
(1988)
Extracranial primitive neuroectodermal tumors
Cancer
(1991)
Cited by (41)
New therapeutic targets in Ewing sarcoma: From pre-clinical proof-of-concept to clinical trials
2015, Bone Cancer: Primary Bone Cancers and Bone Metastases: Second EditionProspects and challenges for the development of new therapies for Ewing sarcoma
2013, Pharmacology and TherapeuticsCitation Excerpt :The lead compound identified from this study was cytarabine, which depressed EWS–FLI1 protein expression, interfered with anchorage independent growth and impaired A673 xenograft growth (Stegmaier et al., 2007). Furthermore, older literature supported the in vitro sensitivity of Ewing sarcoma cells to cytarabine with IC50s that paralleled that of leukemia cell lines (Hofbauer et al., 1993). Unfortunately, the clinical translation of this compound was not successful.
Ewing's Sarcoma
2009, Oncology of Infancy and Childhood: Expert Consult - Online and PrintClinical and cellular pharmacology in relation to solid tumours of childhood
2003, Cancer Treatment Reviews
Copyright © 1992 Published by Elsevier Ltd.